Seven oocyte donors with a levonorgestrel-releasing intrauterine device (LNG-IUD) in situ (group A) underwent ovarian stimulation with human menopausal gonadotrophin (HMG) after goserelin down-regulation, in eight treatment cycles. The donors in a control group (group B, n = 16) were comparable in age, body mass index and parity characteristics. There were no statistically significant differenc...

OBJECTIVE To evaluate safety and efficacy of levonorgestrel-releasing contraceptive implants (Norplant; Leiras Oy, Turku, Finland) in developing countries. METHODS We used controlled cohort methodology. Women attending family planning clinics in eight developing countries selecting Norplant were enrolled, together with women of similar age choosing intrauterine devices (IUDs) or surgical ster...

BACKGROUND The levonorgestrel intrauterine system (LNG IUS) was developed over 30 years ago, but the product is currently too expensive for widespread use in many developing countries. In Kenya, one organization has received donated commodities for 5 years, providing an opportunity to assess impact and potential future role of the product. METHODS We reviewed service statistics on insertions ...

720 CMAJ, July 14, 2015, 187(10) ©2015 8872147 Canada Inc. or its licensors Right now, a woman turned away from her pharmacist has only one option for emergency contraception: getting a copper IUD inserted into her uterus by a physician. Copper IUDs are more than 99% effective at preventing pregnancy, but they can be expensive (up to several hundred dollars) and finding a doctor to insert the d...

Over 30 years of clinical use of emergency contraception has confirmed that such methods substantially reduce the chances of pregnancy, do not entail onerous service provision requirements, and are acceptable to women. The major obstacle to the more widespread use of postcoital methods is a lack of awareness on the part of both potential acceptors and service providers of this important option...

Journal of Family Planning and Reproductive Health Care 2004: 30(2) What is the levonorgestrel-releasing intrauterine system? This Guidance provides recommendations and good practice points regarding the use of a levonorgestrelreleasing intrauterine system, the accepted abbreviation for which is LNG-IUS. The use of a copper-bearing intrauterine device (IUD) has been covered in previous Faculty ...

Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 μg daily. It is highly effective, with a typical-...

INTRODUCTION This is the protocol for an ancillary study to the multicentre Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial, a three-arm randomised trial comparing the effects of depot medroxyprogesterone acetate (DMPA), the levonorgestrel (LNG) implant and the copper intrauterine device (IUD) on HIV incidence (NCT02550067 pre-results). The ancillary study will compare other no...

During perimenopause, i. e. immediately prior to menopause until the end of the first year after a woman’s last menstruation, fertility has not entirely ceased. Ovulation may occur spontaneously thus effective contraception is still necessary especially if a pregnancy is not desired. No contraceptive method is contraindicated only because of the advanced age.Therefore, perimenopausal women can ...

BACKGROUND The use of intrauterine devices as a contraceptive method has been steadily growing in developing countries. Anemia in reproductive-age women is a growing concern in those settings. STUDY DESIGN A systematic review of studies with measured hemoglobin and serum ferritin at baseline and after 1 year of use of copper intrauterine devices (IUDs) or a levonorgestrel-releasing intrauteri...